Compare Illumina, Inc. (ILMN) vs Kenvue Inc. Common Stock (KVUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Kenvue Inc. Common Stock — how do they compare? Illumina, Inc. trades at $278.89 (market cap $39.95B), while Kenvue Inc. Common Stock trades at $17.68 (market cap $34.06B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Kenvue Inc. Common Stock pays a 4.74% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | KVUE | |
|---|---|---|
Market Cap | $39.95B | $34.06B |
Volume | 3,169,503 | 23,267,228 |
Sector | Health | Consumer Staples |
52-Week High | $293.69 | $19.83 |
52-Week Low | $91.00 | $14.11 |
Typical Hold Time | 83 Days | — |
Enterprise Value | $41.31B | $41.56B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Kenvue Inc. Common Stock
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →
